These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 8443391)
1. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391 [TBL] [Abstract][Full Text] [Related]
2. Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin. Okajima K; Abe H; Wagatsuma M; Okabe H; Takatsuki K Am J Hematol; 1995 Jan; 48(1):12-8. PubMed ID: 7832187 [TBL] [Abstract][Full Text] [Related]
3. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto. Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590 [TBL] [Abstract][Full Text] [Related]
4. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Devraj-Kizuk R; Chui DH; Prochownik EV; Carter CJ; Ofosu FA; Blajchman MA Blood; 1988 Nov; 72(5):1518-23. PubMed ID: 3179438 [TBL] [Abstract][Full Text] [Related]
5. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity. de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409 [TBL] [Abstract][Full Text] [Related]
6. Homozygous variant of antithrombin III: AT III Fontainebleau. Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688 [TBL] [Abstract][Full Text] [Related]
7. Clinical and biochemical characterization of antithrombin III Franconville, a variant with Pro 41 Leu mutation. de Roux N; Chadeuf G; Molho-Sabatier P; Plouin PF; Aiach M Br J Haematol; 1990 Jun; 75(2):222-7. PubMed ID: 2372510 [TBL] [Abstract][Full Text] [Related]
8. Homozygous or compound heterozygous qualitative antithrombin III deficiency. Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):335-7. PubMed ID: 7971256 [TBL] [Abstract][Full Text] [Related]
9. Cerebral infarction in a heterozygote with variant antithrombin III. Arima T; Motomura M; Nishiura Y; Tsujihata M; Okajima K; Abe H; Nagataki S Stroke; 1992 Dec; 23(12):1822-5. PubMed ID: 1448834 [TBL] [Abstract][Full Text] [Related]
10. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding. Tripodi A; Krachmalnicoff A; Mannucci PM Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966 [TBL] [Abstract][Full Text] [Related]
11. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa. Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579 [TBL] [Abstract][Full Text] [Related]
12. Antithrombin-III-Stockholm: a codon 392 (Gly----Asp) mutation with normal heparin binding and impaired serine protease reactivity. Blajchman MA; Fernandez-Rachubinski F; Sheffield WP; Austin RC; Schulman S Blood; 1992 Mar; 79(6):1428-34. PubMed ID: 1547341 [TBL] [Abstract][Full Text] [Related]
13. Recurrent leg ulcers and arterial thrombosis in a 33-year-old homozygous variant of antithrombin. Shimizu K; Toriyama F; Ogawa F; Katayama I; Okajima K Am J Hematol; 2001 Apr; 66(4):285-91. PubMed ID: 11279641 [TBL] [Abstract][Full Text] [Related]
14. [Antithrombin deficiency due to heterozygous antithrombin gene mutation and a pedigree study]. Ye X; Feng Y; Jin PP; Zhou XH; Ding QL; Wang XF Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):587-9. PubMed ID: 18246812 [TBL] [Abstract][Full Text] [Related]
15. Antithrombin III Avranches, a new variant with defective serine-protease inhibition--comparison with antithrombin III Charleville. Aiach M; Roncato M; Chadeuf G; Dezellus P; Capron L; Fiessinger JN Thromb Haemost; 1988 Aug; 60(1):94-6. PubMed ID: 3187951 [TBL] [Abstract][Full Text] [Related]
16. Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis. Lane DA; Lowe GD; Flynn A; Thompson E; Ireland H; Erdjument H Br J Haematol; 1987 Aug; 66(4):523-7. PubMed ID: 3663509 [TBL] [Abstract][Full Text] [Related]
17. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin. Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389 [TBL] [Abstract][Full Text] [Related]
18. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver"). Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602 [TBL] [Abstract][Full Text] [Related]
19. Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine. Gandrille S; Aiach M; Lane DA; Vidaud D; Molho-Sabatier P; Caso R; de Moerloose P; Fiessinger JN; Clauser E J Biol Chem; 1990 Nov; 265(31):18997-9001. PubMed ID: 2229057 [TBL] [Abstract][Full Text] [Related]
20. Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis. Raja SM; Chhablani N; Swanson R; Thompson E; Laffan M; Lane DA; Olson ST J Biol Chem; 2003 Apr; 278(16):13688-95. PubMed ID: 12591924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]